# Karyopharm Therapeutics Inc.: financial statements, quarterly

KPTI · Nasdaq · CIK 1503802 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/kpti.md) · [Financials](/companies/kpti/financials.md) · [Filings](/companies/kpti/filings.md) · [Insiders](/companies/kpti/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/kpti/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [36.0](/filings/0000950170-24-121076.md) | [33.7 d](/filings/0001193125-26-049397.md) | [33.1](/filings/0000950170-25-069231.md) | [42.8](/filings/0000950170-25-106238.md) | [38.8](/filings/0001193125-25-261667.md) | [30.5 d](/filings/0001193125-26-049397.md) | [30.0](/filings/0001193125-26-222827.md) | [37.9](/filings/0001193125-26-347906.md) | [44.0](/filings/0001193125-25-261667.md) | [34.1 d](/filings/0001193125-26-049397.md) | [35.1](/filings/0001193125-26-222827.md) | [33.4](/filings/0001193125-26-347906.md) |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [35.6](/filings/0000950170-24-121076.md) | [39.4 d](/filings/0001193125-26-049397.md) | [35.4](/filings/0000950170-25-069231.md) | [38.4](/filings/0000950170-25-106238.md) | [36.1](/filings/0001193125-25-261667.md) | [33.3 d](/filings/0001193125-26-049397.md) | [34.6](/filings/0001193125-26-222827.md) | [32.8](/filings/0001193125-26-347906.md) | [30.5](/filings/0001193125-25-261667.md) | [27.7 d](/filings/0001193125-26-049397.md) | [33.8](/filings/0001193125-26-222827.md) | [29.0](/filings/0001193125-26-347906.md) |
| Selling, general and administrative | $m | [30.8](/filings/0000950170-24-121076.md) | [30.7 d](/filings/0001193125-26-049397.md) | [29.5](/filings/0000950170-25-069231.md) | [31.1](/filings/0000950170-25-106238.md) | [27.6](/filings/0001193125-25-261667.md) | [27.2 d](/filings/0001193125-26-049397.md) | [27.4](/filings/0001193125-26-222827.md) | [28.5](/filings/0001193125-26-347906.md) | [26.6](/filings/0001193125-25-261667.md) | [22.8 d](/filings/0001193125-26-049397.md) | [26.7](/filings/0001193125-26-222827.md) | [25.9](/filings/0001193125-26-347906.md) |
| Operating income | $m | [(31.3)](/filings/0000950170-24-121076.md) | [(37.8) d](/filings/0001193125-26-049397.md) | [(33.8)](/filings/0000950170-25-069231.md) | [(28.1)](/filings/0000950170-25-106238.md) | [(26.3)](/filings/0001193125-25-261667.md) | [(31.3) d](/filings/0001193125-26-049397.md) | [(33.3)](/filings/0001193125-26-222827.md) | [(24.4)](/filings/0001193125-26-347906.md) | [(15.2)](/filings/0001193125-25-261667.md) | [(17.8) d](/filings/0001193125-26-049397.md) | [(26.8)](/filings/0001193125-26-222827.md) | [(22.5)](/filings/0001193125-26-347906.md) |
| Interest expense | $m | [6.1](/filings/0000950170-23-057754.md) | [6.2 d](/filings/0000950170-24-022650.md) | [5.9](/filings/0000950170-24-055672.md) | [8.9](/filings/0000950170-24-091210.md) | [11.4](/filings/0001193125-25-261667.md) | [11.2 d](/filings/0001193125-26-049397.md) | [11.0](/filings/0001193125-26-222827.md) | [11.2](/filings/0001193125-26-347906.md) | [11.0](/filings/0001193125-25-261667.md) | [12.6 d](/filings/0001193125-26-049397.md) | [12.6](/filings/0001193125-26-222827.md) | [13.1](/filings/0001193125-26-347906.md) |
| Income tax | $m | [0.0](/filings/0000950170-24-121076.md) | [0.1 d](/filings/0001193125-26-049397.md) | [0.1](/filings/0000950170-25-069231.md) | [0.1](/filings/0000950170-25-106238.md) | [0.0](/filings/0001193125-25-261667.md) | [(0.1) d](/filings/0001193125-26-049397.md) | [0.0](/filings/0001193125-26-222827.md) | [0.0](/filings/0001193125-26-347906.md) | [0.0](/filings/0001193125-25-261667.md) | [(0.1) d](/filings/0001193125-26-049397.md) | [0.0](/filings/0001193125-26-222827.md) | [0.0](/filings/0001193125-26-347906.md) |
| Net income | $m | [(34.5)](/filings/0000950170-24-121076.md) | [(41.8) d](/filings/0001193125-26-049397.md) | [(37.4)](/filings/0000950170-25-069231.md) | [23.8](/filings/0000950170-25-106238.md) | [(32.1)](/filings/0001193125-25-261667.md) | [(30.8) d](/filings/0001193125-26-049397.md) | [(23.5)](/filings/0001193125-26-222827.md) | [(37.3)](/filings/0001193125-26-347906.md) | [(33.1)](/filings/0001193125-25-261667.md) | [(102) d](/filings/0001193125-26-049397.md) | [(22.4)](/filings/0001193125-26-222827.md) | [(67.0)](/filings/0001193125-26-347906.md) |
| Diluted EPS | $ per share | [(0.30)](/filings/0000950170-24-121076.md) | not reported | [(4.85)](/filings/0000950170-25-069231.md) | [(2.97)](/filings/0000950170-25-106238.md) | [(3.85)](/filings/0001193125-25-261667.md) | not reported | [(2.77)](/filings/0001193125-26-222827.md) | [(4.32)](/filings/0001193125-26-347906.md) | [(3.82)](/filings/0001193125-25-261667.md) | not reported | [(1.24)](/filings/0001193125-26-222827.md) | [(2.32)](/filings/0001193125-26-347906.md) |
| Basic EPS | $ per share | [(0.30)](/filings/0000950170-24-121076.md) | not reported | [(4.85)](/filings/0000950170-25-069231.md) | [2.26](/filings/0000950170-25-106238.md) | [(3.85)](/filings/0001193125-25-261667.md) | not reported | [(2.77)](/filings/0001193125-26-222827.md) | [(4.32)](/filings/0001193125-26-347906.md) | [(3.82)](/filings/0001193125-25-261667.md) | not reported | [(1.02)](/filings/0001193125-26-222827.md) | [(2.32)](/filings/0001193125-26-347906.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [43.7](/filings/0000950170-24-121076.md) | [52.2](/filings/0001193125-26-049397.md) | [30.6](/filings/0000950170-25-069231.md) | [84.8](/filings/0000950170-25-106238.md) | [72.8](/filings/0001193125-25-261667.md) | [62.5](/filings/0001193125-26-049397.md) | [38.8](/filings/0001193125-26-222827.md) | [38.7](/filings/0001193125-26-347906.md) | [37.7](/filings/0001193125-25-261667.md) | [60.5](/filings/0001193125-26-347906.md) | [90.9](/filings/0001193125-26-222827.md) | [55.0](/filings/0001193125-26-347906.md) |
| Current assets | $m | [263](/filings/0000950170-23-057754.md) | [234](/filings/0000950170-25-022765.md) | [198](/filings/0000950170-24-055672.md) | [209](/filings/0000950170-24-091210.md) | [185](/filings/0000950170-24-121076.md) | [156](/filings/0001193125-26-049397.md) | [120](/filings/0000950170-25-069231.md) | [97.9](/filings/0000950170-25-106238.md) | [89.7](/filings/0001193125-25-261667.md) | [103](/filings/0001193125-26-347906.md) | [126](/filings/0001193125-26-222827.md) | [106](/filings/0001193125-26-347906.md) |
| Total assets | $m | [270](/filings/0000950170-23-057754.md) | [240](/filings/0000950170-25-022765.md) | [204](/filings/0000950170-24-055672.md) | [214](/filings/0000950170-24-091210.md) | [189](/filings/0000950170-24-121076.md) | [164](/filings/0001193125-26-049397.md) | [128](/filings/0000950170-25-069231.md) | [105](/filings/0000950170-25-106238.md) | [96.2](/filings/0001193125-25-261667.md) | [108](/filings/0001193125-26-347906.md) | [131](/filings/0001193125-26-222827.md) | [111](/filings/0001193125-26-347906.md) |
| Current liabilities | $m | [62.1](/filings/0000950170-23-057754.md) | [69.5](/filings/0000950170-25-022765.md) | [65.3](/filings/0000950170-24-055672.md) | [57.6](/filings/0000950170-24-091210.md) | [61.5](/filings/0000950170-24-121076.md) | [92.3](/filings/0001193125-26-049397.md) | [90.4](/filings/0000950170-25-069231.md) | [99.2](/filings/0000950170-25-106238.md) | [87.2](/filings/0001193125-25-261667.md) | [92.1](/filings/0001193125-26-347906.md) | [117](/filings/0001193125-26-222827.md) | [134](/filings/0001193125-26-347906.md) |
| Total liabilities | $m | [370](/filings/0000950170-23-057754.md) | [377](/filings/0000950170-25-022765.md) | [373](/filings/0000950170-24-055672.md) | [346](/filings/0000950170-24-091210.md) | [349](/filings/0000950170-24-121076.md) | [350](/filings/0001193125-26-049397.md) | [334](/filings/0000950170-25-069231.md) | [344](/filings/0000950170-25-106238.md) | [365](/filings/0001193125-25-261667.md) | [401](/filings/0001193125-26-347906.md) | [397](/filings/0001193125-26-222827.md) | [441](/filings/0001193125-26-347906.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [(100)](/filings/0000950170-24-121076.md) | [(136)](/filings/0001193125-26-049397.md) | [(169)](/filings/0000950170-25-106238.md) | [(132)](/filings/0001193125-25-261667.md) | [(160)](/filings/0001193125-25-261667.md) | [(186)](/filings/0001193125-26-347906.md) | [(206)](/filings/0001193125-26-347906.md) | [(239)](/filings/0001193125-26-347906.md) | [(269)](/filings/0001193125-25-261667.md) | [(293)](/filings/0001193125-26-347906.md) | [(266)](/filings/0001193125-26-347906.md) | [(330)](/filings/0001193125-26-347906.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(29.5) d](/filings/0000950170-24-121076.md) | [(18.6) d](/filings/0001193125-26-049397.md) | [(43.7)](/filings/0000950170-25-069231.md) | [(38.5) d](/filings/0000950170-25-106238.md) | [(19.5) d](/filings/0001193125-25-261667.md) | [(25.8) d](/filings/0001193125-26-049397.md) | [(39.0)](/filings/0001193125-26-222827.md) | [(18.7) d](/filings/0001193125-26-347906.md) | [(5.9) d](/filings/0001193125-25-261667.md) | [(11.8) d](/filings/0001193125-26-049397.md) | [(22.7)](/filings/0001193125-26-222827.md) | [(24.9) d](/filings/0001193125-26-347906.md) |
| Capital expenditure | $m | [0.0 d](/filings/0000950170-24-121076.md) | [0.0 d](/filings/0001193125-26-049397.md) | [0.2](/filings/0000950170-25-069231.md) | [0.0 d](/filings/0000950170-25-106238.md) | [0.0 d](/filings/0001193125-25-261667.md) | [(0.1) d](/filings/0001193125-26-049397.md) | [0.0](/filings/0000950170-25-069231.md) | [0.0 d](/filings/0000950170-25-106238.md) | [0.0 d](/filings/0001193125-25-261667.md) | [0.0 d](/filings/0001193125-26-049397.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [80.2](/filings/0000950170-23-057754.md) | [113](/filings/0000950170-24-055672.md) | [114](/filings/0000950170-24-091210.md) | [0.1](/filings/0000950170-24-121076.md) | [0.0](/filings/0000950170-25-069231.md) | [0.0](/filings/0000950170-25-106238.md) | [0.0](/filings/0001193125-25-261667.md) | [0.0](/filings/0001193125-26-222827.md) | [0.0](/filings/0001193125-26-347906.md) | [0.0](/filings/0001193125-25-261667.md) | [0.0](/filings/0001193125-26-222827.md) | [0.0](/filings/0001193125-26-347906.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 22,681,460 at 2026-08-06, from the cover of the [10-Q filed 2026-08-13](/filings/0001193125-26-347906.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:41 ET. No prices; not investment advice.